

Highlights from Union Conference & TBScience

November 8-10, 2022

[Link to full Union program | TBScience program](#)

Session times have been converted to Pacific Daylight Time zone (PDT).

All sessions will be available on-demand later the same day until March 31, 2023, for all registered attendees.

Time (PDT)	Session Type	Session	Track/Channel
TUESDAY, NOVEMBER 8			
4:15-4:23am	Oral Abstract	OA04-229-08 Scale-up of 99DOTS for TB treatment supervision: intervention reach and treatment outcomes Oral Presenter: Rebecca Crowder (San Francisco, United States)	Track A: Basic and Translational Research Channel 3
6:00-6:20am	Symposium	SP-06: Evaluation of a standardised TB treatment regimen in patients with multidrug-resistant tuberculosis: STREAM Stage 2 final results STREAM (Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-Resistant) is the first large-scale, multi-country clinical trial to examine shortened regimens for multidrug-resistant TB. Stage 1 of STREAM compared a 9-month short regimen to the then locally used long regimen (approximately 20-month) and showed that the short regimen was non-inferior to the long regimen. STREAM Stage 2 evaluated two additional regimens containing bedaquiline (one of the newest TB drugs), including a 9-month all oral regimen. This symposium will present results of the Stage 2 trial, including efficacy, safety and health economics. Presentations will be followed by a panel discussion on the results and their potential programmatic implications.	Track B3: Clinical trials and operational research for new treatments for TB (for adults and children) Channel 5
6:00-6:08am	E-poster	EP-06-651 Treatment outcomes in young children with rifampicin-resistant TB regimens including bedaquiline and delamanid: a global individual patient data meta-analysis Oral Presenter: Maria Garcia-Cremades (San Francisco, United States)	Track A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments Channel: E-posters (accessible upon demand)
7:45-8:30am	TBScience	TBS-02: TB risk and outcome - co-morbidities and environmental factors - Oral Abstracts Chair: Rada Savic (USA)	TBScience Channel 7
8:12-8:20am	TBScience	TBS-02: Breath Volatile Organic Compounds for the Prediction of Childhood TB Oral Presenter: Robert Castro (San Francisco, United States)	TBScience Channel 7

Time (PDT)	Session Type	Session	Track/Channel
9:15-10:45am	Satellite	<p>Accelerating the development of new TB drugs and regimens</p> <p>UNITE4TB is a public-private partnership with representation from academic institutions, SMEs, public organizations, and pharmaceutical companies. The PAN-TB collaboration is a consortium of philanthropic, non-profit and private sector organizations that aims to accelerate the Phase 2 development of novel “pan-TB” drug regimens for the treatment of TB.</p> <p>These organizations are working on programs to deliver novel phase 2 clinical trials that will accelerate the development of new TB drugs and regimens. The regimens are designed to have little to no drug resistance and an improved safety and tolerability profile, relative to existing options.</p> <p>This session will describe both organizations, their composition, structure and governance. Objectives of the clinical programs will be discussed, focusing on coordination between the two groups, to maximize impact of these programs. These innovative collaborations are establishing a new partnership model to expedite TB clinical research.</p>	Track B3: Clinical trials and operational research for new treatments for TB (for adults and children) Channel 3
9:56-10:08am	Satellite	<p>Biostatistics and Endpoints Speaker: Patrick Phillips (United States)</p>	Track B3: Clinical trials and operational research for new treatments for TB (for adults and children) Channel 3
WEDNESDAY, NOVEMBER 9			
1:00-2:20am	Symposium	<p>SP-10: Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis (TRUNCATE-TB Trial)</p> <p>The TRUNCATE-TB (‘Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis’) Trial is a randomised controlled trial conducted at 18 sites in five countries (Indonesia, the Philippines, Thailand, India and Uganda) and coordinated from Singapore. The trial investigates a treatment strategy comprising an initial 2-month treatment course (using regimens combining standard and repurposed drugs intended to boost regimen sterilising efficacy), followed by close monitoring and early retreatment of relapses. In this session, we will present key data, as well as practical experiences from implementing the trial to evaluate the impact on future approaches to TB programmatic treatment, as well as on the design of future TB clinical trials.</p>	Track B3: Clinical trials and operational research for new treatments for TB (for adults and children) Channel 1
4:15-4:23am	Oral Abstract	<p>LBCOV-2067-09 Epidemiological analysis of mortality among COVID-affected TB patients in Ukraine Oral Presenter: Yana Terleeva (Kyiv, Ukraine)</p>	Track: Late breaker Channel 5
7:35-7:43am	Oral Abstract	<p>OA16-313-09: Process and contextual factors influencing acceptance and completion of isoniazid-rifapentine (3HP) regimen for TB prevention by people living with HIV in Uganda Oral Presenter: Joan Ritar Kasidi (Kampala, Uganda) (3HP project, Cattamanchi)</p>	Track C1: Implementation of TPT Channel 1

Time (PDT)	Session Type	Session	Track/Channel
THURSDAY, NOVEMBER 10			
4:15-4:23am	Oral Abstract	LBCOV-1934-09 How did Covid-19 affect TB diagnostics in Hisar district of Haryana? Oral Presenter: Neerja Arora (New Delhi, India)	Track: Late breaker Channel 5
6:13-6:21am	Oral Abstract	OA23-366-10 Point-of-care C-reactive protein-based TB triage testing for people with and without HIV: a multi-country diagnostic accuracy study Oral Presenter: Danaida Marcelo (Dasmariñas City, Philippines) (R2D2 project, Cattamanchi)	Track B1: TB diagnostics – Operational and clinical studies Channel 3
7:30-8:50am	Oral Abstract	LBTB: The Union/CDC late-breaker session on TB Chair: Rovina Ruslami (BANDUNG, Indonesia) Chair: Patrick Moonan (United States)	Track: Late breaker Channel 2
7:41-7:49am	TBScience	TBS-05: Samples collected and quantified by qPCR show tongue swabs may approach sensitivity of sputum-based TB Dx Oral Presenter: Amy Steadman (Bellevue, WA, United States) (R2D2 project, Cattamanchi)	TBScience Channel 5
7:42-7:49am	Oral Abstract	LBCDC-1937-11 Optimized delivery of isoniazid-rifapentine for tuberculosis prevention among people living with HIV: the 3HP Options Trial Oral Presenter: Allan Musinguzi (Kampala, Uganda) (3HP project, Cattamanchi)	Track: Late-breaker Channel 2
7:49-7:57am	TBScience	TBS-05: Plasma proteomics for the discovery of novel biomarkers for childhood pulmonary tuberculosis Oral Presenter: Peter Wambi (Kampala, Uganda) (COMBO project, Cattamanchi)	TBScience Channel 5
7:56-8:03am	Oral Abstract	LBCDC-2077-11 Changes in immune gene expression in rifampicin-susceptible tuberculosis following treatment with GSK3036656 Oral Presenter: Maja Reimann (Borstel, Germany)	Track: Late-breaker Channel 2
8:04-8:12am	TBScience	TBS-08: A multi-country assessment of digital lung sound analysis to predict pulmonary tuberculosis Oral Presenter: Byron Reeve (Cape Town, South Africa) (R2D2 project, Cattamanchi)	TBScience Channel 7
8:10-8:17am	Oral Abstract	LBCDC-2074-11 High rate of successful outcomes treating RR-TB with a delamanid-bedaquiline regimen in BEAT Tuberculosis: an interim analysis Oral Presenter: Francesca Conradie (Johannesburg, South Africa)	Track: Late-breaker Channel 2
8:12-8:20am	TBScience	TBS-08 Continuous cough monitoring with an AI-enabled mobile phone app for TB evaluation and treatment response Oral Presenter: Lucy Asege (Kampala, Uganda) (R2D2 project, Cattamanchi)	TBScience Channel 7
8:17-8:24am	Oral Abstract	LBCDC-2078-11 Phase 2a trial of GSK3036656 in rifampicin-susceptible, pulmonary tuberculosis: PET/CT scan results Oral Presenter: David Barros-Aguirre (London, United Kingdom)	Track: Late-breaker Channel 2

Time (PDT)	Session Type	Session	Track/Channel
9:15-10:45am	Satellite	<p>SMART4TB: An Ambitious Initiative to Contribute to Ending TB Through Research, Capacity-Strengthening, Community Ownership, and Policy</p> <p>Chair: Richard Chaisson (United States) Chair: Payam Nahid (United States) Organised by: Johns Hopkins University and USAID</p> <p>The mission of the USAID-funded SMART4TB Consortium is to design and implement research studies in partnership with local partners that will identify effective person-centered methods for finding, treating, and preventing TB; to strengthen local capacity to conduct high-quality research; and to engage communities to build demand for new interventions, drive policy change, and improve implementation to reach the End TB targets. This session will describe the bold agenda set forth by the Consortium to leverage an extraordinary investment by USAID to help achieve the END TB goals and to engage with the TB community regarding additional research priorities.</p> <p>9:15am: Live introduction</p> <p>9:20am: What do TB programmes need from research? Viet Nhung Nguyen</p> <p>9:30am: Community partnerships in TB research to END TB. Lindsay McKenna</p> <p>9:40am: Transforming TB diagnostics to reach END TB goals. Adithya Cattamanchi</p> <p>9:50am: Innovations in TB therapies for all: Including children and pregnant women in TB trials. Nicole Salazar-Austin</p> <p>10:20am: Facilitated live discussion and Q&A</p>	Track B1: TB diagnostics – Operational and clinical studies Channel 4
N/A	E-poster	<p>EP-05-649 Sustained costs of 99DOTS following implementation in Uganda Oral Presenter: Joseph Waswa (Kampala, Uganda) (TB REACH project, Cattamanchi)</p>	Track A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments Channel: E-posters (accessible upon demand)
N/A	E-poster	<p>EP-28-876 The role of 99DOTS digital adherence technology to support TB treatment adherence among adolescents Oral Presenter: Peter Wambi (Kampala, Uganda) (TB REACH project, Cattamanchi)</p>	Track A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Time (PDT)	Session Type	Session	Track/Channel
			Channel: E-posters (accessible upon demand)
N/A	E-poster	EP-35-950 The role of continuous cough sound detection for TB treatment monitoring among people living with and without HIV Oral Presenter: Alex Kityamuwesi (Kampala, Uganda) (TB REACH project, Cattamanchi)	Track A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments Channel: E-posters (accessible upon demand)
N/A	TBScience E-poster	Evaluation of Xpert TB Host Response Assay for Triage of Pulmonary Tuberculosis Huy Ha (Hanoi, Vietnam) (R2D2 project, Cattamanchi)	Accessible upon demand